Yazarlar : Breccia M, Loglisci G, Salaroli A, Serrao A, Petrucci L, Mancini M, Alimena G.

Yayın : Leuk Lymphoma.

Yayın Yılı : 2012

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/22280532

Konu : MDS

Literatür İçeriği :  

Abstract

Abstract Efficacy and safety of azacitidine in elderly MDS patients (aged > 65 years) treated outside clinical trial were reported here. Thirty-eight MDS patients received azacitidine (75 mg/m2, schedule 5+2+2): 7 patients were classified as refractory cytopenia with multilineage dysplasia (RCMD), 9 patients as refractory anaemia with excess of blasts (RAEB) type 1, 18 patients as RAEB type 2 and 4 patients as chronic myelomonocytic leukaemia type 2 (CMML-2). According to IWG 2006 criteria, after the first 4 cycles we detected complete remission in 7 patients (CR, 18%), improvement of bone marrow dysplasia and reduction of blasts percentage in 7 patients (partial response, 18%), stable disease in 20 patients (53%) and progression to acute leukaemia in 4 patients (10%). Median overall survival for all patients treated was 16.4 months. Only mild non-hematologic toxicity was detected (grade 1-2 nausea and pruritus) whereas, 55% of patients experienced hematologic side effects (25% grade 3-4 thrombocytopenia and 30% grade 3-4 neutropenia). Our results suggest that advanced age should not preclude effective treatment with azacitidine in non-selected elderly MDS patients.

Literatür Arşivi